AU2020386864A1 - Prodrugs of Fulvestrant - Google Patents

Prodrugs of Fulvestrant Download PDF

Info

Publication number
AU2020386864A1
AU2020386864A1 AU2020386864A AU2020386864A AU2020386864A1 AU 2020386864 A1 AU2020386864 A1 AU 2020386864A1 AU 2020386864 A AU2020386864 A AU 2020386864A AU 2020386864 A AU2020386864 A AU 2020386864A AU 2020386864 A1 AU2020386864 A1 AU 2020386864A1
Authority
AU
Australia
Prior art keywords
group
optionally substituted
aryl
heteroaryl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020386864A
Other languages
English (en)
Inventor
Pathik Subhashchandra BRAHMKSHATRIYA
Vishalgiri Gunvantgiri GOSWAMI
Parva Yogeshchandra Purohit
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kashiv Biosciences LLC
Original Assignee
Kashiv Biosciences LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kashiv Biosciences LLC filed Critical Kashiv Biosciences LLC
Publication of AU2020386864A1 publication Critical patent/AU2020386864A1/en
Assigned to Shivanka Research LLC reassignment Shivanka Research LLC Request for Assignment Assignors: KASHIV BIOSCIENCES, LLC
Assigned to KASHIV BIOSCIENCES, LLC reassignment KASHIV BIOSCIENCES, LLC Request for Assignment Assignors: Shivanka Research LLC
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0072—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/006—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton spiro-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2020386864A 2019-11-24 2020-11-24 Prodrugs of Fulvestrant Pending AU2020386864A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN201921047986 2019-11-24
IN201921047986 2019-11-24
IN202021029084 2020-07-08
IN202021029084 2020-07-08
PCT/IB2020/061065 WO2021100029A2 (en) 2019-11-24 2020-11-24 Prodrugs of fulvestrant

Publications (1)

Publication Number Publication Date
AU2020386864A1 true AU2020386864A1 (en) 2022-06-16

Family

ID=75980095

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020386864A Pending AU2020386864A1 (en) 2019-11-24 2020-11-24 Prodrugs of Fulvestrant

Country Status (7)

Country Link
US (1) US20230137764A1 (https=)
EP (1) EP4061376A4 (https=)
JP (2) JP2023503898A (https=)
CN (1) CN115151260A (https=)
AU (1) AU2020386864A1 (https=)
CA (1) CA3162182A1 (https=)
WO (1) WO2021100029A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4422636A4 (en) * 2021-10-29 2025-09-03 Kashiv Biosciences Llc INECTABLE PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF BREAST CANCER
WO2023103929A1 (zh) * 2021-12-06 2023-06-15 江苏亚虹医药科技股份有限公司 氟维司群衍生物及其制备方法和医药用途
EP4444318A4 (en) * 2021-12-06 2026-01-28 Amneal Pharmaceuticals Llc COMPOUNDS FOR CANCER TREATMENT
CN114716496B (zh) * 2022-04-29 2024-04-02 香港中文大学（深圳） 氟维司群衍生物及氟维司群衍生物制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2176208T3 (en) * 2007-07-30 2015-04-27 Zynerba Pharmaceuticals Inc Prodrugs of cannabidiol, compositions containing prodrugs of cannabidiol and methods of use thereof
US20140079636A1 (en) * 2012-04-16 2014-03-20 Dinesh U. Chimmanamada Targeted therapeutics
US20160060288A1 (en) * 2013-04-18 2016-03-03 Xi'anlibang Pharmaceutical Technology Co., Ltd. Ester derivatives of 7-alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)-estra-1,3,5(10)-triene-3,17beta-diol having anticancer activity and preparation method thereof
WO2014169456A1 (zh) * 2013-04-18 2014-10-23 西安力邦医药科技有限责任公司 7-α-[9-(4,4,5,5,5-五氟戊基亚硫酰基)壬基]-雌甾-1,3,5(10)-三烯-3,17β-二醇及其衍生物的用途
CN103421069A (zh) * 2013-05-23 2013-12-04 中国海洋大学 氟维司群磷酸酯衍生物及其制备方法和应用
EP3738594A1 (en) * 2013-09-10 2020-11-18 Madrigal Pharmaceuticals, Inc. Targeted therapeutics having an hsp90 ligand as binding moiety
WO2019050850A1 (en) * 2017-09-05 2019-03-14 Primetime Life Sciences, Llc BIGUANIDINE DERIVATIVES OF THERAPEUTIC AGENTS, AND PREPARATION METHODS AND METHODS OF USING SAME
JP7384903B2 (ja) * 2018-05-24 2023-11-21 ケーアイ ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー フルベストラントのプロドラッグ

Also Published As

Publication number Publication date
WO2021100029A2 (en) 2021-05-27
EP4061376A2 (en) 2022-09-28
EP4061376A4 (en) 2024-03-13
US20230137764A1 (en) 2023-05-04
JP2023503898A (ja) 2023-02-01
CA3162182A1 (en) 2021-05-27
JP2026032104A (ja) 2026-02-25
WO2021100029A3 (en) 2021-07-01
CN115151260A (zh) 2022-10-04

Similar Documents

Publication Publication Date Title
AU2020386864A1 (en) Prodrugs of Fulvestrant
JP7653092B2 (ja) フルベストラントのプロドラッグ
US11753373B2 (en) Protease inhibitors as antivirals
AU2017246228B2 (en) Soluble C5aR antagonists
ES2731758T3 (es) Derivados de alcanodiil y alquenodiil de c17 del ácido oleanólico y métodos de uso de los mismos
JP2021527666A (ja) Ｗｄ４０反復ドメインタンパク質５（ｗｄｒ５）分解／破壊化合物および使用の方法
JP7759063B2 (ja) プロドラッグ化合物、その製造方法、及び用途
JP2021075570A (ja) アムホテリシンｂの誘導体
JP2018514516A (ja) 水溶性ｌ‐ドーパエステル
TWI870449B (zh) 吡唑化合物，其配製物以及使用該化合物和/或配製物之方法
CA3107377A1 (en) Boronic acid derivatives
KR102961556B1 (ko) 프로드러그 화합물 및 이의 제조 방법과 용도
EP1765850B1 (en) Substituted propane phosphinic acid derivatives
WO2018060317A1 (en) Pyrimidine prodrugs for the treatment of viral infections and further diseases
CA3031562C (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
WO2013013240A2 (en) Macrocyclic compounds and related compositons and methods of use
JP2024542821A (ja) 癌治療のための化合物
JP2024529444A (ja) ＴＮＦ－α生成及び炎症複合体活性抑制新規化合物及びその製造方法

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: SHIVANKA RESEARCH LLC

Free format text: FORMER APPLICANT(S): KASHIV BIOSCIENCES, LLC

PC1 Assignment before grant (sect. 113)

Owner name: KASHIV BIOSCIENCES, LLC

Free format text: FORMER APPLICANT(S): SHIVANKA RESEARCH LLC